SEC Comment Letter for Wave Life Sciences, (WVE) — Mar 7, 2022
Wave Life Sciences, Inc.
Date: March 7, 2022 · CIK: 0001631574 · Accession: 0000000000-22-002504
AI Filing Summary & Sentiment
File numbers found in text: 333-263251
Letter
United States securities and exchange commission logo March 7, 2022 Linda Rockett, Esq. Senior Vice President, General Counsel Wave Life Sciences Ltd. c/o 733 Concord Avenue Cambridge, MA 02138 Re:Wave Life Sciences Ltd. Registration Statement on Form S-3 Filed March 3, 2022 File No. 333-263251 Dear Ms. Rockett: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John P. Condon, Esq.
Show Raw Text
United States securities and exchange commission logo
March 7, 2022
Linda Rockett, Esq.
Senior Vice President, General Counsel
Wave Life Sciences Ltd.
c/o 733 Concord Avenue
Cambridge, MA 02138
Re:Wave Life Sciences Ltd.
Registration Statement on Form S-3
Filed March 3, 2022
File No. 333-263251
Dear Ms. Rockett:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John P. Condon, Esq.